CD96 and neoplasm: Consistent with this finding, the cytotoxicity of T cells engineered to express an anti-HER2 CAR containing CD96 and CD3ζ endodomains against HER2-expressing tumor cells was significantly impaired as compared with counterparts expressing an anti-HER2 CAR containing CD3ζ endodomain alone.